Altered monocyte response to the dengue virus in those with varying severity of past dengue infection.


Journal

Antiviral research
ISSN: 1872-9096
Titre abrégé: Antiviral Res
Pays: Netherlands
ID NLM: 8109699

Informations de publication

Date de publication:
09 2019
Historique:
received: 15 02 2019
revised: 05 07 2019
accepted: 05 07 2019
pubmed: 10 7 2019
medline: 8 7 2020
entrez: 10 7 2019
Statut: ppublish

Résumé

We sought to investigate the differences in monocyte immune responses to the dengue virus (DENV) in those who previously had either severe disease (past SD) or non-severe dengue (past NSD) following a secondary dengue infection. Monocytes from healthy individuals who had either past SD (n = 6) or past NSD (n = 6) were infected at MOI one with all four DENV serotypes following incubation with autologous serum. 36-hours post infection, levels of inflammatory cytokines and viral loads were measured in the supernatant and expression of genes involved in viral sensing and interferon signaling was determined. Monocytes of individuals with past SD produced significantly higher viral loads (p = 0.0426 and cytokines (IL-10 p = 0.008, IL-1β p = 0.008 and IL-6 p = 0.0411) when infected with DENV serotypes they were not immune to, compared to those who has past NSD. Monocytes of individuals with past SD also produced significantly higher viral loads (p = 0.022) and cytokines (IL-10 p < 0.0001, IL-1β < 0.0001 and IL-6 p < 0.0001) when infected with DENV serotypes they were previously exposed to, despite the monocytes being infected in the presence of autologous serum. A significant upregulation of NLRP3 (p = 0.005), RIG-I (0.0004) and IFNB-1 (0.01) genes were observed in those who had past SD compared to past NSD when infected with non-immune DENV serotypes. Monocytes from those with past SD appear to show marked differences in viral loads, viral sensing and production of inflammatory mediators in response to the DENV, when compared to those who experienced past NSD, suggesting that initial innate immune responses may influence the disease outcome.

Identifiants

pubmed: 31288040
pii: S0166-3542(19)30090-7
doi: 10.1016/j.antiviral.2019.104554
pii:
doi:

Substances chimiques

Antibodies, Viral 0
Cytokines 0
IL10 protein, human 0
IL1B protein, human 0
Interleukin-1beta 0
Interleukin-6 0
Interleukin-10 130068-27-8

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

104554

Subventions

Organisme : Medical Research Council
ID : MC_U137881017
Pays : United Kingdom
Organisme : Medical Research Council
ID : G116/150
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 209222/Z/17/Z
Pays : United Kingdom
Organisme : Medical Research Council
ID : G0701693
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UU_12010/5
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_PC_14131
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_PC_14103
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UU_00008/5
Pays : United Kingdom

Informations de copyright

Copyright © 2019 Elsevier B.V. All rights reserved.

Auteurs

Achala Kamaladasa (A)

Centre for Dengue Research, University of Sri Jayawardanapura, Sri Lanka.

Laksiri Gomes (L)

Centre for Dengue Research, University of Sri Jayawardanapura, Sri Lanka.

Ayesha Wijesinghe (A)

Centre for Dengue Research, University of Sri Jayawardanapura, Sri Lanka.

Chandima Jeewandara (C)

Centre for Dengue Research, University of Sri Jayawardanapura, Sri Lanka.

Ying Xiu Toh (YX)

Singapore Immunology Network, Agency for Science, Technology and Research (A*STAR), Singapore.

Deshni Jayathilaka (D)

Centre for Dengue Research, University of Sri Jayawardanapura, Sri Lanka.

Graham S Ogg (GS)

Centre for Dengue Research, University of Sri Jayawardanapura, Sri Lanka; MRC Human Immunology Unit, Weatherall Institute of Molecular Medicine, Oxford NIHR Biomedical Research Centre and University of Oxford, OX3 9DS, UK.

Katja Fink (K)

Singapore Immunology Network, Agency for Science, Technology and Research (A*STAR), Singapore.

G N Malavige (GN)

Centre for Dengue Research, University of Sri Jayawardanapura, Sri Lanka; MRC Human Immunology Unit, Weatherall Institute of Molecular Medicine, Oxford NIHR Biomedical Research Centre and University of Oxford, OX3 9DS, UK. Electronic address: gathsaurie.malavige@ndm.ox.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH